Answers are grounded in this paper and cite their sources.
Nitric oxide (NO) can suppress antitumor immunity, support tumor adaptation, or promote immune-mediated killing, making its therapeutic manipulation highly dependent on exposure. This Review examines how materials control NO source, localization, release kinetics, and chemical fate in cancer immunotherapy, with particular attention to immune checkpoint blockade (ICB). We analyze polymeric donors, nanocarriers, injectable depots, and strategies for restricting endogenous NO production, linking their physicochemical properties to target exposure and immune function. Evidence from checkpoint-treated models is distinguished from mechanisms established with other therapies and from human associations. Comparative analyses separate donor capacity from measured NO exposure, carrier accumulation from cellular delivery, and distant-tumor control from demonstrated immune memory. Four overlapping endogenous contexts, comprising tumor adaptation, myeloid suppression, vascular dysfunction, and inflammatory effector activity, guide intervention design without constituting validated patient categories. We identify testable predictions concerning cellular selectivity, release kinetics, and spatial pharmacodynamic responses. Translation requires measurements that connect material behavior to a defined NO-dependent process while demonstrating preservation of beneficial endothelial and immune functions. This framework provides a basis for evaluating when localized NO delivery or selective inhibition may support ICB, while recognizing the limits of current preclinical and clinical evidence.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: